Plain-English translation of NCT06704893 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new injection treatment called AMNIOGEN®, which is made from placental tissue, to see if it can relieve knee arthritis pain more effectively than existing options. Placental tissue contains natural anti-inflammatory substances that may help reduce the swelling and pain of arthritis. Researchers will compare this medication against two other injection treatments and a placebo to find out which works best.
Current injection treatments for knee arthritis—like steroid injections or hyaluronic acid—don't work well for everyone, especially older patients or those with certain health conditions. This trial exists to find out whether a placental tissue injection could offer a better, more reliable option for people suffering from knee arthritis.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive one injection directly into your knee—either the new placental tissue treatment, a traditional hyaluronic acid injection, or a saline placebo. You will be randomly assigned to one of these four groups. The study team will track your pain and function over time to see how well the treatment works compared to the alternatives. You'll need to report any additional pain medications you take during the study and avoid certain treatments during the trial period.
AI-generated summary from trial data · Jun 21, 2026 · Not medical advice
Taiwan